期刊论文

【摘要】

The safety of progestogens as a class has drawn much attention after the publication of data from the Women’s Health Initiative (WHI) trial, particularly with respect to cardiovascular disease. Depending on the chemical structure, pharmacokinetics, receptor affinity and potency of action, progestogens have a divergent range of properties that may translate to very different clinical effects. The purpose of this review is to describe the role of varied progestogens in hormone replacement therapy (HRT), especially focusing on blood lipids, which are the most important parameters for assessing cardiovascular disease risk.

【授权许可】

CC BY
© The Author(s). 2017

【预览】

附件列表
Files	Size	Format	View
RO202311105069829ZK.pdf	413KB	PDF	download

【参考文献】

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]

Lipids in Health and Disease
The effects of progesterones on blood lipids in hormone replacement therapy
Review
Weijie Tian¹ Yifan Jiang²
[1] Department of Obstetrics and Gynecology, Guizhou Provincial People’s Hospital, NO.83, Zhongshan East Road, 550002, Guiyang, Guizhou, People’s Republic of China;Guizhou Provincial Center for Drug Reevaluation, 550001, Guiyang, Guizhou, People’s Republic of China;
关键词: Hormone replacement therapy; Progestogens; Lipids;
DOI : 10.1186/s12944-017-0612-5
received in 2017-09-14, accepted in 2017-11-07, 发布年份 2017
来源: Springer
PDF


	文献评价指标
	下载次数：31次	浏览次数：0次

【 摘 要 】

【 授权许可】

【 预 览 】

【 参考文献 】

【摘要】

【授权许可】

【预览】

【参考文献】